By Johanna BennettDo you want safe, or sexy?That’s the question facing biotechnology investors, according to a recent research note from Cowen analysts that previews the sector’s second-quarter financial results.“In heady times, large cap provides a safe haven, smid caps the sex appeal,” reads the note.After shrugging off a selloff in late June, the Nasdaq Biotechnology index has gained 30% since […]
Related ALXNUS Stock Futures Drop Ahead Of Economic DataStrensiq Receives Marketing Approval in Japan for Treatment of Patients with HypophosphatasiaBy and large, the number of shares short in the leading biotech and emerging pharmaceutical stocks shrank between the June 15 and June 30 settlement dates.The trend was particularly noticeable in Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Gilead Sciences, Inc. (NASDAQ: […]
Avalanche Biotech (NASDAQ:AAVL)Shares of Avalanche Biotech fell as much as 40% in after-hours trading on June 15, 2015 after the company announced results from its phase 2 wet-age related macular degeneration — wet-AMD — trial. The drop is huge but many investors should be assured that the drop was justified because the results were mediocre at best. In addition if […]
By Ben LevisohnSunTrust Robinson Humphrey’s Edward Nash and team offer five biotech stocks for the next six months:
Cempra (CEMP) ($50 PT), our top pick based on near-term clinical and commercial success potential. We recently met with management and it was reiterated that the second Phase III study of solithromycin in CABP (SOLITAIRE-IV) remains on track to report top-line data by […]
Updated 6/10 Biotech ETFs lag overall in 1.4% rally. Materials, financials and technology lead. Large cap biotechs doing well.
Rayno portfolio winners today: ALXN, BIIB, GILD, RHHBY etc
Rapid Fire Re-Balancing of ETFs into More Speculative Names
Is the Tail Wagging the Dog?
We have published a number of reports on Life Science ETFs (2/4/15) in the past and noticed changes lately that reflect a […]
By Ben LevisohnBarclays’ Geoff Meacham and Jonathan Eckard are feeling good about biotech stocks like Biogen (BIIB) and Alexion Pharmaceuticals (ALXN) heading into the summer. They explain why:
Associated Press
[The] Nasdaq Biotech Index index has outperformed the broader market eight out of 10 times over the summer period (Memorial Day to Labor Day) and in 2Q/3Q, there are a number of meaningful […]
Related ARIAMorning Market GainersBenzinga’s Top #PreMarket GainersThe Vetr community has downgraded $ARIA to 3-Stars(Vetr)Related CLVSGoldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis OncologyBenzinga’s Volume MoversStifel analyst Brian Klein published abstracts Thursday from the 2015 ASCO annual meeting.Klein’s following comments along with current ratings were intended to provide investors with “meaningful insight into ongoing clinical activities for various […]
I found some very interesting information when conducting research on small-cap biotech stocks. Most disturbing: Well-respected analysts recommended an abundance of small-cap biotech stocks that have since been annihilated. My job is to give readers ideas where they can start research to not only potentially make money, but to stay away from dangerous names. It’s not going to do any […]
By
Timothy Hay
Biography
CONNECT
Biography
Biotechnology companies have been going public in record numbers, and many of them have been immediately embraced by public-market investors once their stock starts trading.But does that mean the sector is in a bubble?The chief executives of two venture-backed companies that went public spoke at the National Venture Capital Association’s annual conference in San Francisco. They said the good days for […]
By Ben LevisohnRBC’s Michael Yee and team aren’t too worried about biotech stocks like Gilead Sciences (GILD), Celgene (CELG), and Biogen Idec (BIIB) despite the biotech sector’s big drop last week:
Biotech felt another volatile pullback (similar to March) in the last week of April, pulling back 9% in a week. Investors had their helmets on as we went right through […]
